{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:13:28Z","timestamp":1791051208427,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ygyno.2005.07.129","type":"journal-article","created":{"date-parts":[[2005,10,4]],"date-time":"2005-10-04T18:22:59Z","timestamp":1128450179000},"page":"116-127","source":"Crossref","is-referenced-by-count":52,"title":["Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma"],"prefix":"10.1016","volume":"100","author":[{"given":"Laurent","family":"Brard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius O.","family":"Granai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.07.129_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2005.07.129_bib2","unstructured":"Cancer facts and figures, American Cancer Society, 2005"},{"key":"10.1016\/j.ygyno.2005.07.129_bib3","first-page":"340","article-title":"Chemotherapy of advanced ovarian cancer","volume":"25","author":"McGuire","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib4","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate","volume":"38","author":"Engel","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.07.129_bib5","first-page":"24","article-title":"Innovative therapies for advanced ovarian cancer","volume":"27","author":"Trimble","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib6","doi-asserted-by":"crossref","first-page":"11255","DOI":"10.1021\/bi00161a001","article-title":"Iron metabolism\u2014new perspectives in view","volume":"31","author":"Crichton","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.ygyno.2005.07.129_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0891-5849(95)02111-6","article-title":"Iron-induced carcinogenesis: the role of redox regulation","volume":"20","author":"Toyokuni","year":"1996","journal-title":"Free Radical Biol. Med."},{"issue":"8651","key":"10.1016\/j.ygyno.2005.07.129_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(89)92857-2","article-title":"Iron, asbestos, and carcinogenicity","volume":"1","author":"Weinberg","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2005.07.129_bib9","first-page":"3574","article-title":"Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase","volume":"7","author":"Green","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(01)00218-9","article-title":"Iron chelators as therapeutic agents for the treatment of cancer","volume":"42","author":"Richardson","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-5793(94)00755-1","article-title":"Iron deprivation-induced apoptosis in HL-60 cells","volume":"350","author":"Fukuchi","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ygyno.2005.07.129_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1012211828319","article-title":"Desferriexochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells","volume":"69","author":"Pahl","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2005.07.129_bib13","first-page":"1073","article-title":"Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells","volume":"61","author":"Fan","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib14","doi-asserted-by":"crossref","first-page":"7903","DOI":"10.1073\/pnas.91.17.7903","article-title":"Iron reverses impermeable chelator inhibition of DNA synthesis in CCl 39 cells","volume":"91","author":"Alcain","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2005.07.129_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1189\/jlb.0903435","article-title":"Mechanism of apoptosis induced by S100A8\/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions","volume":"76","author":"Ghavami","year":"2004","journal-title":"J. Leukocyte Biol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0009-2797(03)00087-5","article-title":"Involvement of intracellular glutathione in zinc deficiency-induced activation of hepatic stellate cells","volume":"146","author":"Kojima-Yuasa","year":"2003","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ygyno.2005.07.129_bib17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0969-8043(02)00192-6","article-title":"Radiolabeled peptides in the diagnosis and therapy of oncological diseases","volume":"57","author":"Weiner","year":"2002","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.ygyno.2005.07.129_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1517\/14656566.4.10.1763","article-title":"Pharmacotherapy of iron overload in thalassaemic patients","volume":"4","author":"Ceci","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ygyno.2005.07.129_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hep.1840110407","article-title":"Effect of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines","volume":"11","author":"Hann","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.ygyno.2005.07.129_bib20","first-page":"428","article-title":"Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells","volume":"23","author":"Haq","year":"1995","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2184.1999.3210063.x","article-title":"Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3","volume":"32","author":"Ido","year":"1999","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ygyno.2005.07.129_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000164105","article-title":"Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13","volume":"65","author":"Kovar","year":"1997","journal-title":"Pathobiology"},{"key":"10.1016\/j.ygyno.2005.07.129_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1046\/j.1523-1747.2000.00119.x","article-title":"Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors","volume":"115","author":"Simonart","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/ob.1996.v175.a73595","article-title":"Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat","volume":"175","author":"Rose","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-1759(86)90215-2","article-title":"Use of MTT colorimetric assay to measure cell activation","volume":"94","author":"Gerlier","year":"1986","journal-title":"J. Immunol. Methods"},{"issue":"4571","key":"10.1016\/j.ygyno.2005.07.129_bib26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1126\/science.7123245","article-title":"Monoclonal antibody to 5-bromo- and 5-iodo-deoxyuridine: a new reagent for detection of DNA replication","volume":"218","author":"Gratzner","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2005.07.129_bib27","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/S0024-3205(00)00901-2","article-title":"The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells","volume":"67","author":"Rosenberger","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.ygyno.2005.07.129_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0091-679X(08)61707-0","article-title":"Assays of cell viability: discrimination of cells dying by apoptosis","volume":"41","author":"Darzynkiewicz","year":"1994","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcb.10615","article-title":"Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages","volume":"90","author":"Gumireddy","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev.biochem.68.1.383","article-title":"Mammalian caspases: structure, activation, substrates, and functions during apoptosis","volume":"68","author":"Earnshaw","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib31","first-page":"31","article-title":"The role of iron in cell cycle progression and the proliferation of neoplastic cells","volume":"1603","author":"Le","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2005.07.129_bib32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/0929867033457638","article-title":"The role of iron chelation in cancer therapy","volume":"10","author":"Buss","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4615-0593-8_12","article-title":"Therapeutic potential of iron chelators in cancer therapy","volume":"509","author":"Richardson","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.ygyno.2005.07.129_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.07.129_bib36","first-page":"685","article-title":"The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell","volume":"54","author":"Richardson","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib37","first-page":"402","article-title":"Examination of the anti-proliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of Triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311","volume":"9","author":"Chaston","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib38","first-page":"303","article-title":"Inhibition of DNA synthesis in CCL 39 cells by impermeable iron chelators","volume":"41","author":"Alcain","year":"1997","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.ygyno.2005.07.129_bib39","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2174\/1568026043387269","article-title":"Iron chelators in cancer chemotherapy","volume":"4","author":"Buss","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib40","first-page":"110","article-title":"Iron chelation therapy","volume":"4","author":"Hershko","year":"2005","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.ygyno.2005.07.129_bib41","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/0929867033457593","article-title":"Iron chelator research: past, present, and future","volume":"10","author":"Tam","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib42","first-page":"189","article-title":"Imaging tumors with peptide-based radioligands","volume":"45","author":"Behr","year":"2001","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/j.ygyno.2005.07.129_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00002142-199103000-00006","article-title":"Clinical applications of contrast agents in body imaging","volume":"3","author":"Bydder","year":"1991","journal-title":"Top Magn. Reson. Imaging"},{"key":"10.1016\/j.ygyno.2005.07.129_bib44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0704507","article-title":"Desferrithiocin is a more potent antineoplastic agent than desferrioxamine","volume":"135","author":"Kicic","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0009-2797(99)00166-0","article-title":"Apoptosis induced by chelation of intracellular zinc is associated with depletion of cellular reduced glutathione level in rat hepatocytes","volume":"125","author":"Nakatani","year":"2000","journal-title":"Chem.-Biol. Interact."},{"key":"10.1016\/j.ygyno.2005.07.129_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/asheducation-2001.1.47","article-title":"Secondary iron overload","author":"Kushner","year":"2001","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.ygyno.2005.07.129_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7827-1-66","article-title":"Chemoresistance in human ovarian cancer: the role of apoptotic regulators","volume":"1","author":"Fraser","year":"2003","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib48","first-page":"3","article-title":"Apoptosis, oncosis, and necrosis","volume":"146","author":"Majno","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib49","first-page":"7189","article-title":"Deferoxamine inhibition of human neuroblastoma viability and proliferation","volume":"48","author":"Becton","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib50","first-page":"685","article-title":"The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell","volume":"54","author":"Richardson","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.1995.tb08927.x","article-title":"Iron chelators induce apoptosis in proliferating cells","volume":"89","author":"Hileti","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/0003-4819-120-6-199403150-00008","article-title":"Iron-chelating agents in non-iron overload conditions","volume":"120","author":"Voest","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2005.07.129_bib53","first-page":"1749","article-title":"Antineuroblastoma activity of desferrioxamine in human cells","volume":"47","author":"Blatt","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib54","first-page":"4929","article-title":"Effects of a single course of desferrioxamine in neuroblastoma patients","volume":"50","author":"Donfrancesco","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00000421-199208000-00009","article-title":"Desferrioxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation\u2013chemotherapy regimen in patients with advanced neuroblastoma","volume":"15","author":"Donfrancesco","year":"1992","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.129_bib56","first-page":"3968","article-title":"Neuroblastoma sensitivity to growth inhibition by desferrioxamine. Evidence for a block in G1 phase of the cell cycle","volume":"53","author":"Brodie","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.129_bib57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0959-8049(95)00068-T","article-title":"Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results","volume":"31A","author":"Donfrancesco","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.07.129_bib58","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B","article-title":"Effect of iron chelators on proliferation and iron uptake in hepatoma cells","volume":"92","author":"Kicic","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2005.07.129_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V98.3.842","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: IV. The mechanisms involved in inhibiting cell-cycle progression","volume":"98","author":"Gao","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2005.07.129_bib60","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/carcin\/21.5.943","article-title":"Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines","volume":"21","author":"Rakba","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2005.07.129_bib61","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood.V92.4.1384","article-title":"Tumor cell cytotoxicity of a novel metal chelator","volume":"92","author":"Torti","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2005.07.129_bib62","doi-asserted-by":"crossref","first-page":"25568","DOI":"10.1074\/jbc.M110345200","article-title":"Activation of caspase pathways during iron chelator-mediated apoptosis","volume":"277","author":"Greene","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2005.07.129_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00001813-199306000-00004","article-title":"D-CeaT: a breakthrough for patients with neuroblastoma","volume":"4","author":"Donfrancesco","year":"1993","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2005.07.129_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Safety"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580500675X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580500675X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T01:44:42Z","timestamp":1586483082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580500675X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S009082580500675X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.07.129","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}